{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-128084","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.001637+00:00","generated_at":"2026-06-07T09:36:22.536911+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acura extends $4.67M related-party promissory note maturity to March 31, 2024","bullets":["Original note of $4,669,279 at 5.25% interest matured Dec 31, 2023; maturity extended to March 31, 2024.","Note held by AD Pharma, which owns ~66% of Acura common stock (excluding warrants to purchase 10M shares).","John Schutte controls AD Pharma and directly owns ~14% of Acura.","Overdue amounts bear default interest at 7.5%; default triggers include bankruptcy and non-payment.","Extension provides short-term liquidity relief but highlights ongoing financial pressure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-128084","json":"https://secwatch.observer/filing/0001104659-23-128084.json","markdown":"https://secwatch.observer/filing/0001104659-23-128084.md","text":"https://secwatch.observer/filing/0001104659-23-128084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465923128084/0001104659-23-128084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465923128084/tm2333501d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:36:22.536911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bc2947f8df68ccfe7bf343287a7785606deb7eb","claim":"ACURA PHARMACEUTICALS, INC amended loan of $4,669,279 with Abuse Deterrent Pharma, LLC at 5.25% maturing March 31, 2024.","evidence_excerpt":"#1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note (the “Note”). Amendment #1 has an effective date of December 7, 2023. This Note totaling $4,669,279 bears interest at 5.25% and had a maturity date of December 31, 2023, at which time all principal and interest was due. Amendment #1 changes the maturity date of the Note to March","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465923128084/0001104659-23-128084-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$4,669,279"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"March 31, 2024"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}